Boston Therapeutics, a company focusing on the development of diabetes treatments using complex carbohydrate chemistry, continues to make progress in raising public awareness of its diabetes drug's potential. The company announced in a news release today it will be presenting at the Elsevier Therapeutic Area Partnerships 2013 Conference, where it was selected as one of 10 "Top Projects to Watch" within the category of cardiovascular/metabolic diseases. Mr. Kenneth A. Tassey, Jr., President of Boston Therapeutics, will be presenting information about the diabetes drug PAZ320 at the conference.
From 2:15 to 3:05 PM on Tuesday, November 19, 2013, at the Hyatt Regency in Boston, Mr. Tassey will discuss how PAZ320 was recently found to exhibit Type 2 diabetes management efficacy in 45% of patients in an FDA Phase 2a clinical trial. PAZ320 is a non-systemic chewable tablet that lets patients manage their post-meal blood sugar levels, by targeting enzymes that digest sugar during digestion.
Mr. Tassey said, "TAP 2013 promises to be one of the key meetings of the year within the cardiovascular/metabolic disease area. We are pleased with this opportunity to educate attendees about the potential benefits of PAZ320, and are honored to be named a 'Top Project to Watch' by the independent panel."
Since it was first started almost a decade ago, the conference has come to be one of the premier events in biopharmaceutical partnering. The event gathers the leading industry entrepreneurs and thought leaders to hear of the latest developments in biopharmaceuticals as well as provide quality networking opportunities. The "Top Projects to Watch" picks are determined by a panel of independent experts who screen hundreds of compounds and select the ones with the most potential as future products. Their criteria include: large market, large unmet need, with increasing opportunity; history of the molecule and drug; strong science; strong company; diversity of indications; potential for new opportunities beyond the initial indications; and multilevel partnering opportunities.
For more information, visit: bostonti.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com